The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
In vivo CAR T cell generation to treat cancer and autoimmune disease
Abstract
Chimeric antigen receptor (CAR) T cell therapies have transformed treatment of B cell malignancies. However, their broader application is limited by complex manufacturing processes and the necessity for lymphodepleting chemotherapy, restricting patient accessibility. We present an in vivo engineering strategy using targeted lipid nanoparticles (tLNPs) for messenger RNA delivery to specific T cell subsets. These tLNPs reprogrammed CD8 + T cells in both healthy donor and autoimmune patient samples, and in vivo dosing resulted in tumor control in humanized mice and B cell depletion in cynomolgus monkeys. In cynomolgus monkeys, the reconstituted B cells after depletion were predominantly naïve, suggesting an immune system reset. By eliminating the requirements for complex ex vivo manufacturing, this tLNP platform holds the potential to make CAR T cell therapies more accessible and applicable across additional clinical indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sharp, P. M., & Li, W.-H. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.3.1281 · Cited by 3,992
CAR T cells produced in vivo to treat cardiac injury
Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2022) · Science · doi:10.1126/science.abm0594 · Cited by 1,400
Self-citationLong-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,382
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Morris, E. C., Neelapu, S. S., Giavridis, T., & Sadelain, M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00547-6 · Cited by 1,104
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
Müller, F., Taubmann, J., Bucci, L., Wilhelm, A., Bergmann, C., Völkl, S., Aigner, M., Rothe, T., Minopoulou, I., Tur, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2308917 · Cited by 1,095
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen, A., Müller, F., Mougiakakos, D., Böltz, S., Wilhelm, A., Aigner, M., Völkl, S., Simon, D., Kleyer, A., Munoz, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02017-5 · Cited by 1,092
CAR T Cells Produced in vivo to Treat Cardiac Injury
Rurik, J. G., Tombácz, I., Yadegari, A., Fernández, P. O. M., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2023) · HAL · Cited by 926
Self-citationDecade-long leukaemia remissions with persistence of CD4+ CAR T cells
Melenhorst, J. J., Chen, G. M., Wang, M., Porter, D. L., Chen, C., Collins, M. A., Gao, P., Bandyopadhyay, S., Sun, H., Zhao, Z., et al. (2022) · Nature · doi:10.1038/s41586-021-04390-6 · Cited by 923
Self-citationConrad, N., Misra, S., Verbakel, J. Y., Verbeke, G., Molenberghs, G., Taylor, P. N., Mason, J., Sattar, N., McMurray, J. J. V., McInnes, I. B., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00457-9 · Cited by 879
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
Mougiakakos, D., Krönke, G., Völkl, S., Kretschmann, S., Aigner, M., Kharboutli, S., Böltz, S., Manger, B., Mackensen, A., & Schett, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107725 · Cited by 610
Miller, F. W. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102266 · Cited by 516
Parayath, N. N., Stephan, S. B., Koehne, A. L., Nelson, P. S., & Stephan, M. T. (2020) · Nature Communications · doi:10.1038/s41467-020-19486-2 · Cited by 446
CAR T-cell therapy in autoimmune diseases
Schett, G., Mackensen, A., & Mougiakakos, D. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01126-1 · Cited by 430
Alabanza, L., Pegues, M., Geldres, C., Shi, V., Wiltzius, J. J. W., Sievers, S. A., Yang, S., & Kochenderfer, J. N. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.013 · Cited by 351
Self-citationImmune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome
Hines, M. R., Knight, T. E., McNerney, K. O., Leick, M. B., Jain, T., Ahmed, S., Frigault, M. J., Hill, J. A., Jain, M. D., Johnson, W. T., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.03.006 · Cited by 338
Brudno, J. N., Lam, N., Vanasse, D., Shen, Y.-W., Rose, J. J., Rossi, J., Xue, A., Bot, A., Scholler, N., Mikkilineni, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0737-3 · Cited by 311
Self-citationT cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Ghilardi, G., Fraietta, J. A., Gerson, J. N., Van Deerlin, V. M., Morrissette, J. J. D., Caponetti, G. C., Paruzzo, L., Harris, J. C., Chong, E. A., Susanibar Adaniya, S. P., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02826-w · Cited by 270
Self-citationBillingsley, M. M., Gong, N., Mukalel, A. J., Thatte, A. S., El‐Mayta, R., Patel, S. K., Metzloff, A. E., Swingle, K. L., Han, X., Xue, L., et al. (2024) · Small · doi:10.1002/smll.202304378 · Cited by 268
Urits, I., Swanson, D., Swett, M. C., Patel, A., Berardino, K., Amgalan, A., Berger, A. A., Kassem, H., Kaye, A. D., & Viswanath, O. (2020) · Neurology and Therapy · doi:10.1007/s40120-020-00208-1 · Cited by 262
Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
Taraseviciute, A., Tkachev, V., Ponce, R., Turtle, C. J., Snyder, J. M., Liggitt, H. D., Myerson, D., Gonzalez-Cuyar, L., Baldessari, A., English, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1368 · Cited by 256
Pecher, A.-C., Hensen, L., Klein, R., Schairer, R., Lutz, K., Atar, D., Seitz, C., Stanger, A., Schneider, J., Braun, C., et al. (2023) · JAMA · doi:10.1001/jama.2023.8753 · Cited by 251
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
Good, Z., Spiegel, J. Y., Sahaf, B., Malipatlolla, M. B., Ehlinger, Z. J., Kurra, S., Desai, M. H., Reynolds, W. D., Wong Lin, A., Vandris, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01960-7 · Cited by 248
T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity
Moulton, V. R., & Tsokos, G. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78087 · Cited by 245
Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
Zhang, L., More, K. R., Ojha, A., Jackson, C. B., Quinlan, B. D., Li, H., He, W., Farzan, M., Pardi, N., & Choe, H. (2023) · npj Vaccines · doi:10.1038/s41541-023-00751-6 · Cited by 244
Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells
Barrett, D. M., Zhao, Y., Liu, X., Jiang, S., Carpenito, C., Kalos, M., Carroll, R. G., June, C. H., & Grupp, S. A. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.070 · Cited by 220
Self-citationAbrams, M. T., Koser, M. L., Seitzer, J., Williams, S. C., DiPietro, M. A., Wang, W., Shaw, A. W., Mao, X., Jadhav, V., Davide, J. P., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.208 · Cited by 209
Sedic, M., Senn, J. J., Lynn, A., Laska, M., Smith, M., Platz, S. J., Bolen, J., Hoge, S., Bulychev, A., Jacquinet, E., et al. (2018) · Veterinary Pathology · doi:10.1177/0300985817738095 · Cited by 195
CD19-CAR T-cell therapy induces deep tissue depletion of B cells
Tur, C., Eckstein, M., Velden, J., Rauber, S., Bergmann, C., Auth, J., Bucci, L., Corte, G., Hagen, M., Wirsching, A., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2024-226142 · Cited by 187
Kheirolomoom, A., Kare, A. J., Ingham, E. S., Paulmurugan, R., Robinson, E. R., Baikoghli, M., Inayathullah, M., Seo, J. W., Wang, J., Fite, B. Z., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121339 · Cited by 171
Ramwadhdoebé, T. H., van Baarsen, L. G. M., Boumans, M. J. H., Bruijnen, S. T. G., Safy‐Khan, M., Berger, F. H., Semmelink, J. F., van der Laken, C. J., Gerlag, D. M., Thurlings, R. M., et al. (2018) · Rheumatology · doi:10.1093/rheumatology/key428 · Cited by 163
Nicolai, C. J., Parker, M. H., Qin, J., Tang, W., Ulrich-Lewis, J. T., Gottschalk, R., Cooper, S. E., Lopez, S. A. H., Parrilla, D., Mangio, R. S., et al. (2024) · Blood · doi:10.1182/blood.2024024523 · Cited by 148
Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input
Wang, V., Gauthier, M., Decot, V., Reppel, L., & Bensoussan, D. (2023) · Cancers · doi:10.3390/cancers15041003 · Cited by 143
Nakou, M., Katsikas, G., Sidiropoulos, P. I., Bertsias, G. K., Papadimitraki, E. D., Raptopoulou, A., Koutala, H., Papadaki, H. Α., Kritikos, H. D., & Boumpas, D. T. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2798 · Cited by 136
Comparative United States autoimmune disease rates for 2010–2016 by sex, geographic region, and race
Roberts, M. H., & Erdei, E. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102423 · Cited by 132
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
Gajra, A., Zalenski, A. A., Sannareddy, A., Jeune‐Smith, Y., Kapinos, K. A., & Kansagra, A. J. (2022) · Pharmaceutical Medicine · doi:10.1007/s40290-022-00428-w · Cited by 124
Infectious complications of CAR T-cell therapy: a clinical update
Stewart, A. G., & Henden, A. S. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211036773 · Cited by 102
A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy
Boulch, M., Cazaux, M., Cuffel, A., Ruggiu, M., Allain, V., Corre, B., Loe-Mie, Y., Hosten, B., Cisternino, S., Auvity, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101161 · Cited by 78
Metadata
- Authors
- Hunter, T. L., Bao, Y., Zhang, Y., Matsuda, D., Riener, R., Wang, A., Li, J. J., Soldevila, F., Chu, D. S. H., Nguyen, D. P., Yong, Q.-C., Ross, B., Nguyen, M., Vestal, J., Roberts, S., Galvan, D., Vega, J. B., Jhung, D., Butcher, M., Nguyen, J., Zhang, S., Fernandez, C., Chen, J., Herrera, C., Kuo, Y., Pica, E. M., Mondal, G., Mammen, A. L., Scholler, J., Tanis, S. P., Sievers, S. A., Frantz, A. M., Adams, G. B., Shawver, L., Farzaneh-Far, R., Rosenzweig, M., Karmali, P. P., Bot, A. I., June, C. H., & Aghajanian, H.
- Venue
- Science
- Published
- 2025-06-19
- Volume
- 388
- Issue
- 6753
- Pages
- 1311-1317
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4411505807
- Cited by
- 330
- References
- 37
- FWCI
- 120.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.